Glucagon-like peptide-1 receptor agonists in pediatric healthcare

Pediatric obesity and youth-onset type 2 diabetes (T2D) are increasingly prevalent chronic diseases linked to high cardiometabolic morbidity and long-term cardiovascular risks. To complement lifestyle changes, glucagon-like peptide-1 receptor agonists (GLP-1RAs)—such as liraglutide and semaglutide—have emerged as powerful tools for pediatric weight and glycemic management. Clinical evidence confirms that these agents drive significant weight loss in adolescents, and liraglutide is effective in children as young as six. Furthermore, GLP-1RAs improve glycemic control in youth with T2D through glucose-dependent insulin and glucagon regulation, delayed gastric emptying, and central appetite modulation. Safe clinical integration requires precise patient selection, gradual dose titration, and behavioral support. Clinicians must screen for strict precautions like medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. Continuous monitoring is essential to track gastrointestinal side effects, gallbladder disease, nutritional adequacy, growth, pubertal development, and psychological well-being. Beyond direct clinical care, significant hurdles remain regarding equitable access, insurance coverage, treatment persistence, and psychosocial factors. While current evidence supports their implementation, critical knowledge gaps persist regarding optimal treatment duration, comparative effectiveness, and the role of emerging incretin-based therapies. The chronic administration of these agents in pediatric obesity and type 2 diabetes mandates rigorous longitudinal surveillance of their effects on reproductive health, next-generation outcomes, and prolonged off-target safety.

Authors

Institutions

Publication Details

Journal
Journal of Cardiovascular Pharmacology
Published
2026-11-19
DOI
https://doi.org/10.1097/fjc.0000000000001905
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Glucagon-like peptide-1 receptor agonists in pediatric healthcare

George W. Booz, Ghadir Amin, Angela Monafo, Giuseppe Biondi-Zoccai et al.
Journal of Cardiovascular Pharmacology
Diabetes Treatment and Management
article

Glucagon-like peptide-1 receptor agonists in pediatric healthcare

George W. Booz, Ghadir Amin, Angela Monafo, Giuseppe Biondi-Zoccai, Madhav Singla, Jessica Jacob
article en

Abstract

Pediatric obesity and youth-onset type 2 diabetes (T2D) are increasingly prevalent chronic diseases linked to high cardiometabolic morbidity and long-term cardiovascular risks. To complement lifestyle changes, glucagon-like peptide-1 receptor agonists (GLP-1RAs)—such as liraglutide and semaglutide—have emerged as powerful tools for pediatric weight and glycemic management. Clinical evidence confirms that these agents drive significant weight loss in adolescents, and liraglutide is effective in children as young as six. Furthermore, GLP-1RAs improve glycemic control in youth with T2D through glucose-dependent insulin and glucagon regulation, delayed gastric emptying, and central appetite modulation. Safe clinical integration requires precise patient selection, gradual dose titration, and behavioral support. Clinicians must screen for strict precautions like medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and pregnancy. Continuous monitoring is essential to track gastrointestinal side effects, gallbladder disease, nutritional adequacy, growth, pubertal development, and psychological well-being. Beyond direct clinical care, significant hurdles remain regarding equitable access, insurance coverage, treatment persistence, and psychosocial factors. While current evidence supports their implementation, critical knowledge gaps persist regarding optimal treatment duration, comparative effectiveness, and the role of emerging incretin-based therapies. The chronic administration of these agents in pediatric obesity and type 2 diabetes mandates rigorous longitudinal surveillance of their effects on reproductive health, next-generation outcomes, and prolonged off-target safety.

Journal of Cardiovascular Pharmacology
University of Mississippi Medical Center (US), Maria Cecilia Hospital (IT), Sapienza University of Rome (IT)
Diabetes Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon